Mechanisms of action of bisphosphonates

Annual Review of Pharmacology and Toxicology

Volumn 38, Issue , 1998, Pages 375-388

  Rodan, Gideon A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Bone; Osteoclasts; Resorption inhibitors

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE MINERAL; CELL LEVEL; CHOLESTEROL SYNTHESIS; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HYPERCALCEMIA; OSTEOCLAST; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; TISSUE LEVEL;

EID: 0031800988     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.38.1.375     Document Type: Review

References (60)

1. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, et al. 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333:1437-43
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, et al. 1996. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-41
3. Cummings SR, Black DM, Thompson DE. 1997. Alendronate reduces the risk of vertebral fractures in women without preexisting vertebral fractures: results of the fracture intervention trial. J. Bone Miner. Res. 12(Suppl. 1):S149 (Abstr.)
4. Sins E, Weinstein S, Altman R, Conte JM, Favus M, et al. 1996. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J. Clin. Endocrinol. Metab. 81:961-67
5. Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA. 1996. Duration of response with oral clodronate in Paget's disease of bone. Bone 18:1285-90
6. Fleisch H. 1991. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-44
7. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, et al. 1993. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J. Clin. Oncol. 11:1618-23
8. Pecherstorfer M, Herrmann Z, Body J-J, Manegold C, Degardin M, et al. 1996. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J. Clin. Oncol. 14:268-76
9. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, et al. 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1785-91
10. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, et al. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334:488-93
11. Weinstein RS. 1997. Long-term aminobisphosphonate treatment of fibrous dysplasia: spactacular increase in bone density. J. Bone Miner. Res. 12:1314-15
12. Reid IR, King AR, Alexander CJ, Ibbertson HK. 1988. Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (ABD). Lancet i:143-46
13. Falcini F, Trapani S, Ermini M, Brandi ML. 1996. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif. Tissue Int. 58:166-69
14. Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, et al. 1994. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J. Periodontal Res. 29:35-40
15. Shanbhag AS, Hasselman CT, Rubash HE. 1997. Inhibition of wear-debris mediated osteolysis in a canine total hip arthroplasty model. Clin. Orthop. 344: In press
16. Schenk R, Eggli P, Fleisch H, Rosini S. 1986. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat, Calcif. Tissue Int. 38:342-49
17. Van Beek E, Lowik C, Que I, Papapoulos S. 1996. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner. Res. 11:1492-97
18. Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RGG, et al. 1995. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol. Pharmacol. 47:398-402
19. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, et al. 1993. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92:2577-86
20. Boyce RW, Paddock CL, Gleason JR, Sietsma WK, Eriksen EF. 1995. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J. Bone Miner. Res. 10:211-21
21. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. 1994. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol Metab. 79:1693-700
22. Balena R, Markatos A, Seedor JG, Gentile M, Stark C, et al. 1996. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J. Pharmacol. Exp. Ther. 276:277-83
23. Paddock C, Youngs T, Eriksen E, Boyce R. 1995. Validation of wall thickness estimates obtained with polarized light microscopy using multiple fluorochrome labels: correlation with erosion depth estimates obtained by lamellar counting. Bone 16:381-83
24. Favus M, Emkey R, Leite M, Devogelaer JP, Rodriquez J, et al. 1997. Five-year treatment of osteoprosis in postmenopausal women with oral alendronate: effects on bone mass and turnover and safety. J. Bone Miner. Res. 12(Suppl. 1):S150 (Abstr.)
25. Shen V, Birchman R, Xu R, Otter M, Wu DD, et al. 1995. Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. J. Clin. Invest. 96:2331-38
26. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, et al. 1997. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 82:620-28
27. Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, et al. 1996. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc. Assoc. Am. Physicians 108:230-38
28. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. 1996. Human protein tyrosine phosphatase-σ: alternalive splicing and inhibition by bisphosphonates. J. Bone Miner. Res. 11:535-43
29. Fratzl P, Schreiber S, Roschger P, LaFage M-H, Rodan G, Klaushofer K. 1996. Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle x-ray scattering and backscattered electron imaging study. J. Bone Miner. Res. 11:248-53
30. Meunier PJ, Boivin G. 1997. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 21:373-77
31. Rodan GA. 1997. Bone mass homeostasis and bisphosphonate action. Bone 20:1-4
32. Hughes DE, MacDonald BR, Russell RGG, Gowen M. 1989. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83:1930-35
33. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, et al. 1996. Protein-tyrosine phosphatase activity regulates osteoclast formation and funciton: inhibition by alendronate. Proc. Natl. Acad. Sci. USA 93:3068-73
34. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. 1993. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91:2004-11
35. Vitte C, Fleisch H, Guenther HL. 1996. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-33
36. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM. 1986. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1:27-39
37. Van Beek ER, Lowik CWGM, Papapoulos SE. 1997. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone 20:335-40
38. Seedor JG, Quartuccio HA, Thompson DD. 1991. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner. Res. 6:339-46
39. Sato M, Grasser W, Endo N, Akins R, Simmons H, et al. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88:2095-105
40. Wesolowski G, Duong LT, Lakkakorpi PT, Nagy RM, Tezuka K, et al. 1995. Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells. Exp. Cell Res. 219:679-86
41. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, et al. 1996. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137:2187-90
42. Owens JM, Fuller K, Chambers TJ. 1997. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J. Cell. Physiol. 172:79-86
43. Plasmans CMT, Jap PHK, Kuypers W, Slooff TJJ. 1980. Influence of adiphosphonate on the cellular aspect of young bone tissue. Calcif. Tissue Int. 32:247-56
44. Salo J, Lenenkari P, Mulari M, Metsikko K, Vaananen HK. 1997. Removal of osteoclast bone resorption products by transcytosis. Science 276:270-73
45. Nesbitt SA, Horton MA. 1997. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-69
46. Schlesinger PH, Blair HC, Teitelbaum SL, Edwards JC. 1997. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J. Biol. Chem. 272:18636-43
47. Rodan GA, Rodan SB. 1995. The cells of bone. In Osteoporosis: Etiology, Diagnosis, and Management, Second Edition, ed. B Riggs, LJ Melton III, pp. 1-39. Philadelphia: Lippincott-Raven
48. 3H-etidronate in rat and mouse bones. Bone 19:281-90
49. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, et al. 1995. A possible mechanism of specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-44
50. Rogers MJ, Xiong X, Ji X, Monkkonen J, Russell RGG, et al. 1997. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharm. Res. 14:625-30
51. Zimolo Z, Wesolowski G, Rodan GA. 1995. Acid extrusion is induced by osteoclast attachment to bone: inhibition by alendronate and calcitonin. J. Clin. Invest. 96:2277-83
52. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, et al. 1995. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1478-87
53. Hughes DE, Dai AH, Tiffee JC, Li HH, Mundy GR, Boyce BF. 1996. Estrogen promotes apoptosis of murine osteoclasts mediated by TGFβ. Nat. Med. 2:1132-36
54. Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, et al. 1982. Long-term effects of dichloromethylene diphosphonate (C12 MDP) on skeletal lesions in multiple myeloma. Metab. Bone Dis. Relat. Res. 4:163-68
55. Rogers MJ, Brown RJ, Hodkin V, Blackbum GM, Russell RGG, Watts DJ. 1996. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 224:863-69
56. Ciosek CP Jr., Magnin DR, Harrity TW, Logan JVH, Dickson JK Jr., et al. 1993. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268:24832-37
57. Luckman SP, Hughes DE, Chilton KM, Coxon FP, Holen I, et al. 1997. Bisphosphonates act by inhibiting protein prenylation. J. Bone Miner. Res. 12(Suppl. 1):S194 (Abstr.)
58. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, et al. 1997. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20:399-404
59. +-ATPase. J. Bone Miner. Res. 11:1498-507
60. Fleisch H. 1991. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. London/New York: Parthenon. 35 pp.